Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sangamo Therapeutics
The total study duration is up to 15 years of follow-up post BIVV003 and/or ST-400 infusion.
Age
18–45
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Received treatment with BIVV003 or ST-400 in one of the parent studies (ACT16222, ST- 400-01) or any future studies with BIVV003
Capable of giving signed informed consent (and if applicable assent)
You may not be if
Unable to comply with study visit schedule or study procedures
Any other reason that, in the opinion of the Investigator or Medical Monitor, would render the participant unsuitable for participation in the study The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
